0
₹0 0
Nextgen Biotech

Call us:

menu

Bevacirel (100mg / 400mg) - Bevacizumab Injections

Bevacirel (100mg / 400mg) - Bevacizumab Injections

Bevacirel is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is used in the treatment of various cancers by inhibiting tumor angiogenesis and thereby slowing tumor growth and metastasis.

Select the packing Size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Bevacizumab
Brand Name: Bevacirel
Strengths Available: 100mg/4ml and 400mg/16ml
Packing: Single-use vial
Manufacturer: Reliance Life Sciences Pvt Ltd
Form: Concentrated solution for intravenous infusion
Category: Monoclonal antibody / Anti-VEGF / Anti-cancer therapy
 
Product Introduction:
Bevacirel contains Bevacizumab, a targeted therapy that binds to VEGF-A, preventing it from interacting with its receptors on endothelial cells. This action inhibits the formation of new blood vessels that tumors need for growth and survival. Bevacirel is typically used in combination with chemotherapy for treating several solid tumors.
Uses:
Bevacirel is indicated for the treatment of:
  1. Metastatic colorectal cancer (in combination with 5-FU-based chemotherapy)
  2. Non-small cell lung cancer (NSCLC) – non-squamous type
  3. Metastatic renal cell carcinoma (mRCC)
  4. Glioblastoma multiforme
  5. Cervical cancer (persistent, recurrent, or metastatic)
  6. Ovarian cancer and fallopian tube carcinoma
Storage Instructions:
  1. Store at 2°C–8°C (refrigerated)
  2. Do not freeze
  3. Protect from light
  4. Discard unused portion of the vial
  5. Do not shake the vial
How It Works (Mechanism of Action):
Bevacizumab is a VEGF inhibitor. It binds to VEGF-A, blocking its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on endothelial cells. This action inhibits angiogenesis—the process of forming new blood vessels—thus starving tumors of nutrients and oxygen and inhibiting their growth and spread.
Side Effects:
Common side effects:
  1. Hypertension
  2. Fatigue
  3. Diarrhea
  4. Stomatitis
  5. Nosebleeds
  6. Headache
Serious side effects:
  1. Gastrointestinal perforations
  2. Hemorrhage (e.g., pulmonary or GI bleeding)
  3. Arterial thromboembolic events (stroke, MI)
  4. Wound healing complications
  5. Nephrotic syndrome / Proteinuria
  6. Reversible posterior leukoencephalopathy syndrome (RPLS)
Dosage (Typical Recommended Dose):
  1. Colorectal cancer: 5–10 mg/kg every 2 weeks
  2. NSCLC & glioblastoma: 10–15 mg/kg every 2 or 3 weeks
  3. Renal cell carcinoma / Cervical cancer: 15 mg/kg every 3 weeks
  4. Dosing is weight-based and given as IV infusion over 90 minutes (can be reduced to 30 minutes if well-tolerated)
Method of Administration:
  1. Administered as an intravenous infusion
  2. Do not administer as an IV push or bolus
  3. First infusion over 90 minutes, subsequent infusions over 60 or 30 minutes
  4. Dilute with 0.9% NaCl solution before administration
  5. Should be given by a trained healthcare provider
Precautions:
  1. Do not initiate in patients with recent surgery or active bleeding
  2. Discontinue at least 28 days before major surgery
  3. Monitor blood pressure and urinary protein levels regularly
  4. Use caution in patients with cardiovascular disease or history of thromboembolism
  5. Not recommended during pregnancy or breastfeeding
Drug Interactions:
  1. May potentiate chemotherapy-related toxicities
  2. Increased risk of bleeding with NSAIDs or anticoagulants
  3. No significant CYP450 metabolism – low interaction with liver enzyme-modifying drugs
Allergies:
  1. Contraindicated in patients with hypersensitivity to Bevacizumab or its components
  2. Allergic reactions may include rash, dyspnea, bronchospasm, or anaphylaxis
Overdose Information:
  1. Overdose may lead to severe hypertension or bleeding
  2. No specific antidote; treat symptomatically
  3. Monitor vital signs and provide supportive care
Missed Dose Instructions:
  1. If a dose is missed, administer as soon as possible
  2. Resume treatment as per standard dosing schedule
  3. Consult the oncologist for dose adjustments or rescheduling
Additional Notes:
  1. Patients should avoid major surgery during treatment due to impaired wound healing
  2. Routine monitoring of urinalysis, blood pressure, and complete blood count (CBC) is advised
  3. Inform patients about early signs of bleeding, thrombosis, or hypertension
  4. Female patients of reproductive age should use effective contraception during and for at least 6 months after treatment

In The Same Category

Cart